Literature DB >> 30570851

Correlations of MRP1 gene with serum TGF-β1 and IL-8 in breast cancer patients during chemotherapy.

Xiaoming Zhuang1, Jingmei Wang.   

Abstract

PURPOSE: To investigate the expressions of multidrug resistance-associated protein 1 (MRP1) gene, serum transforming growth factor beta-1 (TGF-β1) and interleukin-8 (IL-8) in patients with breast cancer during chemotherapy, and to analyze their correlations in chemotherapy.
METHODS: 346 breast cancer patients admitted to the Department of Surgery (Breast) of Nanjing Drum Tower Hospital from March 2015 to December 2017 were included as study subjects. All selected patients received chemotherapy in our hospital. Quantitative reverse transcription- polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA) were adopted to detect the expression levels of MRP1 mRNA, as well as MRP1, TGF-β1 and IL-8 proteins in patients before chemotherapy and at 1, 2, 4 and 8 weeks after chemotherapy. Correlations of MRP1 protein/mRNA with clinical features of patients were analyzed, and Pearson's correlation analysis was performed to examine correlations of MRP1 protein/mRNA with TGF-β1 and IL-8 proteins.
RESULTS: The expressions of MRP1 mRNA as well as MRP1, TGF-β1 and IL-8 proteins were increased with the prolongation of chemotherapy time, and there were statistically significant differences between the two time points (p<semi;0.05). No correlations of MRP1 with the clinical patient features with breast cancer were found. Pearson's correlation analysis showed that the expression level of MRP1 was positively correlated with the expression levels of TGF-β1 (r=0.732, p=0.012) and IL-8 (r=0.709, p=0.018), and the expression level of TGF-β1 was positively related to that of IL-8 (r=0.714, p=0.015).
CONCLUSION: With the prolongation of chemotherapy time in breast cancer patients, the expression level of MRP1 also increased which may affect the therapeutic effect of chemotherapy in breast cancer patients and lead to drug resistance. TGF-β1 and IL-8 may be closely associated with the mechanism of drug resistance in MRP1-guided breast cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30570851

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  7 in total

1.  MicroRNA-765 alleviates the malignant progression of breast cancer via interacting with EZH1.

Authors:  Zhen Zeng; Yichen Yang; Hengyu Wu
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

2.  Targeting specificity protein 1 with miR-128-3p overcomes TGF-β1 mediated epithelial-mesenchymal transition in breast cancer: An in vitro study.

Authors:  Lakshmi Vineela Nalla; Piyush Gondaliya; Kiran Kalia; Amit Khairnar
Journal:  Mol Biol Rep       Date:  2022-04-29       Impact factor: 2.742

Review 3.  TGF-β Signaling and Resistance to Cancer Therapy.

Authors:  Maoduo Zhang; Ying Yi Zhang; Yongze Chen; Jia Wang; Qiang Wang; Hezhe Lu
Journal:  Front Cell Dev Biol       Date:  2021-11-30

4.  Effect of Poly(methacrylic acid) on the Cytokine Level in an In Vivo Tumor Model.

Authors:  Olga V Zhukova; Evgenia V Arkhipova; Tatiana F Kovaleva; Daria A Zykova; Natalya A Dubovskaya
Journal:  Molecules       Date:  2022-07-18       Impact factor: 4.927

Review 5.  Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression.

Authors:  Kristen Fousek; Lucas A Horn; Claudia Palena
Journal:  Pharmacol Ther       Date:  2020-09-24       Impact factor: 12.310

6.  Long-chain non-coding RNA GACAT1 promotes development and progression of breast cancer by targeting microRNA-875-3p.

Authors:  Qinghua Wang; Jie Xue; Qingfang Ren; Xiaona Li; Xiaoli Qiu
Journal:  Oncol Lett       Date:  2020-01-24       Impact factor: 2.967

Review 7.  At the Intersection of Cardiology and Oncology: TGFβ as a Clinically Translatable Therapy for TNBC Treatment and as a Major Regulator of Post-Chemotherapy Cardiomyopathy.

Authors:  Andrew Sulaiman; Jason Chambers; Sai Charan Chilumula; Vishak Vinod; Rohith Kandunuri; Sarah McGarry; Sung Kim
Journal:  Cancers (Basel)       Date:  2022-03-19       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.